Induction of Vascular Insulin Resistance and Endothelin-1 Expression and Acceleration of Atherosclerosis by the Overexpression of Protein
Kinase C-β Isoform in the Endothelium molecule-1 (VCAM-1). 6 Expression of eNOS and VCAM-1 can play an important role in the activation of endothelial cells, 9, 10 which is a key initial step for atherosclerosis. Nitric oxide (NO) produced by eNOS activation is the most important endothelium-derived relaxing factor, and it protects the artery from atherosclerosis by multiple mechanisms. 11 VCAM-1 has an important role in regulating the binding of leukocytes to endothelial cells, and its reduction can attenuate the development of atherosclerosis. In insulin-resistant states, such as obesity and type 2 diabetes mellitus, selective inhibition of the IRS/PI3K/ Akt pathway, but not mitogen-activated protein kinase (MAPK) cascade, is probably because of abnormal elevation of metabolites, such as free fatty acids and glucose. 12 One mechanism causing the selective inhibition of insulin action is likely because of protein kinase C (PKC) activation, which has been shown to be a consistent feature in the endothelium in diabetes mellitus or insulin resistance. 13 PKC activation, especially the PKC-β isoform, has been reported to selectively inhibit insulin activation of Akt and eNOS in endothelial cells of diabetic animals and patients by decreasing the phosphorylation of Akt at Ser473 and eNOS at Ser1177. 14, 15 We have characterized the effects of PKC activation on multiple steps of the insulin signaling cascade from the receptor to Akt phosphorylation in endothelial cells and have identified a novel phosphorylation site on p85 subunit of PI3K (threonine 86), which is partially responsive to PKC activation and blunts insulin activation of Akt/eNOS in endothelial cells. 16 In addition, mice with whole-body PKC-β knockout exhibited decreased severity of atherosclerosis, further supporting its role in the atherosclerotic process. 17 However, whether PKC-β activation in the endothelium can inhibit insulin action and accelerate atherosclerosis has not been reported. In this study, we have characterized the effects of overexpressing PKC-β2 isoform selectively to the endothelium on insulin signaling and action in the arteries and on the development of atherosclerosis.
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Methods Animals
Mice with endothelial-specific overexpression of PKC-β2 isoform were generated as previously described. 18 The transgene was injected into the embryos of pure C57/BL6J mice, and the background of the transgenic mice is C57/BL6J. This was crossed with apoE −/− mice that were purchased from the Jackson Laboratory (Bar Harbor, ME), also on C57/BL6J background. The following primers were used for PKC-β2 isoform genotyping: 5′-ATGGATTACAAG GATGACGACGATAAG-3′ and 5′-AGTGGCTGCAGAAGGTGGGCTGCT-3′. Male mice were fed a Western diet (Harland; 42% calories from fat, containing 0.15% cholesterol) starting at 6 weeks of age and continued for 12 weeks. All protocols for animal use and euthanasia were reviewed and approved by the Animal Care Committee of the Joslin Diabetes Center. They are in accordance with National Institutes of Health guidelines following the standards established by the Animal Welfare Acts and by the documents entitled Principles for Use of Animals and Guide for the Care and Use of Laboratory Animals. Endothelial cell culture, glucose tolerance tests, insulin tolerance tests, quantification of atherosclerotic lesion size in aorta, immunohistochemistry, collagen staining, vascular reactivity studies, Western blotting, real-time polymerase chain reaction analysis, leukocyte endothelial cell adhesion, angiotensin II (Ang II) infusion, measurement of big endothelin-1 (ET-1), and ET-1 were performed as described in the Online Data Supplement.
Statistical Analysis
Comparisons of the 2 groups were made using paired or unpaired t test, as appropriate. Comparison among >2 groups was performed by 1-way ANOVA, followed by the post hoc analysis with paired or unpaired t test, to evaluate statistical significance between the 2 groups. Statistical significance was defined as P<0.05. In text and graphs, data are presented as mean±SD.
Results

Insulin Signaling in the Endothelium
Endothelial-targeted PKC-β2 transgenic/apoE −/− [Tg(Prkcb) apoE −/− ] mice were generated by cross-breeding endothelialspecific PKC-β2 transgenic mice [Tg(Prkcb] with apoE −/− mice. Levels of PKC-β2 mRNA increased by 32±4-fold (P<0.01, data not shown) and PKC-β2 protein increased by 2-fold ( Figure 1A and 1B) in cultured lung endothelial cells from Tg(Prkcb)apoE −/− mice compared with that from apoE −/− mice. Expressions of PKC-β2 mRNA levels in macrophages and smooth muscle cells (SMCs) were not different between apoE −/− and Tg(Prkcb)apoE −/− mice (data not shown). We have reported that the loss of insulin receptors on endothelial cells exacerbated atherosclerosis, which correlated to decreased phosphorylation of eNOS and increased expression of VCAM-1. 6 Insulin receptor tyrosine phosphorylation after insulin stimulation was not different between the 2 groups of mice (Online Figure IA and IB). Insulin-induced Akt/eNOS activation was determined in primary cultured endothelial cells from apoE −/− and Tg(Prkcb)apoE −/− mice. Insulin increased Akt Ser473 phosphorylation (p-Akt) by 9.4±0.9-fold ( Figure 1C and 1E) and increased eNOS Ser1176 (mouse site, equivalents of human Ser1177 and bovine Ser1179) phosphorylation (p-eNOS) by 4.3±0.8-fold ( Figure 1C and 1D) in apoE −/− mice. However, insulin-stimulated p-Akt was attenuated by 42% (P<0.01) and eNOS Ser1176 phosphorylation was reduced by 39% (P<0.01) in Tg(Prkcb)apoE −/− mice compared with apoE −/− mice ( Figure  1C-1E ). Insulin signaling also was studied in vivo by intravenous infusion of insulin, and p-eNOS Ser1176 was measured in the femoral artery. Insulin increased p-eNOS Ser1176 by 1.7±0.5-fold in the femoral artery of apoE −/− mice ( Figure  1F and 1G). The basal level of p-eNOS Ser1176 was 49% lower in the femoral artery of Tg(Prkcb)apoE −/− mice than in that of apoE −/− mice (P<0.05; Figure 1F and 1G). The effect of insulin on p-eNOS Ser1176 was impaired by 25% in Tg(Prkcb)apoE −/− mice compared with that in apoE −/− mice (P<0.05; Figure 1F and 1G). We reported that PKC activation phosphorylated threonine 86 of P85α and blunted insulin Akt/eNOS signaling. 16 Activation of PKC by phorbol 12-myristate 13-acetate (PMA) increased P85 phosphorylation in primary cultured endothelial cells of both apoE −/− mice and Tg(Prkcb)apoE −/− mice. The P85 phosphorylation increased by 1.59±0.07-fold in endothelial cells from Tg(Prkcb)apoE −/− mice compared with that from apoE −/− mice ( Figure 1H and 1I; P<0.05). Insulin-induced eNOS phosphorylation also was measured in aortic endothelial cells and was observed to be increased by 1.86±0.80-fold in apoE −/− mice (P<0.05). However, insulin-induced eNOS phosphorylation was inhibited in Tg(Prkcb)apoE −/− mice (Online Figure IIIA and IIIB). Insulin-induced extracellular signal-regulated kinase (ERK) activation also was studied because it may play a role in promoting the development of atherosclerosis. 19 The basal ERK phosphorylation was increased by 1.82±0.90-fold in endothelial cells from Tg(Prkcb)apoE −/− mice (P<0.05) compared with that from apoE −/− mice. Insulin increased ERK phosphorylation by 1.26±0.2-fold in Tg(Prkcb)apoE −/− mice, but not in apoE −/− mice (Online Figure IC and ID).
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Apoptosis in Endothelial Cells
Apoptosis induced by withdrawing growth factors was determined in endothelial cells from both groups of mice. Withdrawing growth factors increased DNA fragmentation in both groups of mice, but it was lower in endothelial cells from Tg(Prkcb)apoE −/− mice than that from apoE −/− mice (Online Figure IE) .
Systemic Metabolic and Vascular Functional Parameters
All mice were fed high-fat (42%) diet chow. The body weight did not differ between apoE −/− and Tg(Prkcb)apoE −/− mice after 12 weeks of high-fat feeding (30.7±5.5 vs 28.5±4.6 g; Online Figure IIA ). Blood pressure, as measured by tail vein plethysmography, was similar for systolic blood pressure (112±6 vs 121±10 mm Hg) and diastolic blood pressure (94±6 vs 96±6 mm Hg) between apoE −/− and Tg(Prkcb)apoE −/− mice (Online Figure IIB) . Levels of total cholesterol (462.5±161.6 vs 406.8±125.2 mg/dL) and triglycerides (151.0±82.2 vs 116.4±47.4 mg/dL) in plasma were not different after highfat feeding (Online Figure IIC and IID). The lipoprotein profile of cholesterol also was characterized by fast protein liquid chromatography to assess very-low-density lipoprotein, low-density lipoprotein, and high-density lipoprotein properties, which did not differ between the 2 groups of animals (Online Figure IIE ). Blood glucose levels during intraperitoneal glucose tolerance and insulin tolerance tests were similar between apoE −/− and Tg(Prkcb)apoE −/− mice (Online Figure IIF and IIG). Therefore, overexpression of PKC-β2 in the endothelium did not change whole-body glucose tolerance, systemic insulin sensitivity, plasma lipids, or blood pressure.
Arterial Responses to Acetylcholine and Sodium Nitroprusside
Functionally, pressure myograph was used to determine whether impaired eNOS phosphorylation in Tg(Prkcb)apoE −/− mice affected arterial dilation. When arterial dilation induced by acetylcholine (Ach) was normalized by the effect of 10 μmol/L sodium nitroprusside (SNP), responses to multiple concentrations of Ach were impaired in Tg(Prkcb)apoE −/− mice compared with apoE −/− mice (Figure 2A Figure 2B ). However, responses to SNP at concentrations from 30 nmol/L to 10 μmol/L were not different between apoE −/− mice and Tg(Prkcb)apoE −/− mice.
Expression of VCAM-1 and Leukocyte-Endothelial Cell Adhesion
Because insulin can inhibit VCAM-1 expression in the endothelium via the IRS/Akt pathway, 6 the basal levels of VCAM-1 mRNA were characterized and found to be increased by 3.5±2.4-fold (P<0.01) in cultured lung endothelial cells from Tg(Prkcb)apoE −/− mice compared with those from apoE −/− mice ( Figure 3A ). The addition of PMA, an activator of PKC, increased VCAM-1 mRNA by 4±2.6-fold and 14±4.5fold in cultured lung endothelial cells from apoE −/− mice and Tg(Prkcb)apoE −/− mice, respectively ( Figure 3A ). However, protein expression of VCAM-1 was increased by 1.8±0.6-fold in cultured lung endothelial cells from Tg(Prkcb)apoE −/− mice versus apoE −/− mice at basal conditions ( Figure 3B ). Insulin inhibited VCAM-1 protein by 44±5% in cells from apoE −/− mice ( Figures 3B and 3C) . In contrast, the addition of insulin did not decrease VCAM-1 expression in endothelial cells from Tg(Prkcb)apoE −/− mice ( Figures 3B and 3C) .
Functionally, attachments of fluorescent-labeled RAW 264.7 macrophages to endothelial monolayer were determined by spectrometer. PMA increased leukocyte-endothelial cell binding by 2.1±0.2-fold compared with vehicle in cultured lung endothelial cells from apoE −/− mice ( Figure 3D ). Preincubation of cells with insulin inhibited PMA-induced leukocyte-endothelial cell binding by 36% (1.4±0.1-fold vs 2.1±0.2-fold; P<0.01; Figure 3D ). Leukocyte-endothelial cell binding was increased by 2.0±0.1-fold (P<0.01) in cultured lung endothelial cells from Tg(Prkcb)apoE −/− mice compared with those from apoE −/− mice ( Figure 3D ). However, insulin was unable to decrease PMA-induced leukocyte-endothelial cell binding in cells from Tg(Prkcb)apoE −/− mice ( Figure 3D ). The increase in VCAM-1 protein after PMA stimulation was comparable with the effect of PMA on leukocyte binding to endothelium. Similarly, insulin decreased PMA-induced VCAM-1 protein, which is comparable with leukocyte binding to endothelium ( Figures  3E and 3F) . Basal VCAM-1 protein expression increased in Tg(Prkcb)apoE −/− mice. PMA increased VCAM-1 protein expression by 1.48±0.26-fold in apoE −/− mice, which was inhibited by insulin in endothelial cells from apoE −/− mice. However, the inhibitory effect of insulin on PMA-induced VCAM-1 expression was impaired in endothelial cells from Tg(Prkcb)apoE −/− mice ( Figure 3E and 3F) . Basal VCAM-1 protein expressions also were measured in aortic endothelial cells and were found to be 2.28±0.47-fold higher in Tg(Prkcb)apoE −/− mice than apoE −/− mice (P<0.05; Online Figure IIIC and IIID).
Ang II Actions and ET-1 Expression
PKC-β isoform activation also can cause insulin-independent effects. We studied the actions of Ang II on the expression of platelet-derived growth factor and ET-1 in the aorta because the actions of these cytokines have been shown to be increased in the vascular wall by diabetes mellitus or insulin-resistant states. [20] [21] [22] [23] Basal ET-1 mRNA expressions in the aorta of apoE −/− mice and Tg(Prkcb)apoE −/− mice were not different. Ang II infusion increased ET-1 mRNA levels by 1.9±0.4-fold compared with vehicle in the aorta of apoE −/− mice ( Figure 4A) . Interestingly, the actions of Ang II on ET-1 mRNA expression were greater in the aorta of Tg(Prkcb)apoE −/− mice compared with that in apoE −/− mice by Figure 4A ). Plateletderived growth factor-α/β mRNA expressions at basal level and after Ang II infusion were not different between apoE −/− mice and Tg(Prkcb)apoE −/− mice (data not shown). Because the half-life of ET-1 protein is only 40 seconds, it is difficult to detect changes in the aorta. Thus, we measured changes of big ET-1, a precursor of ET-1, which has a half-life of 30 minutes. 24 The protein levels of big ET-1 in the aorta from Tg(Prkcb)apoE −/− mice were 2.4-fold higher than the levels of apoE −/− mice at basal condition (16.0±3.3 vs 6.6±0.6 ng/mg aorta; P<0.01; Figure 4B ). Compared with vehicle, Ang II infusion also increased big ET-1 protein by 1.8-fold in the aorta from apoE −/− mice (12.1±3.3 vs 6.6±0.6 ng/mg aorta; P<0.05; Figure 4B ). In Tg(Prkcb)apoE −/− mice, Ang II infusion increased the expression of big ET-1 protein in the aorta by 85% compared with that of apoE −/− mice (22.1±3.8 vs 12.1±3.3 ng/mg aorta; P<0.05; Figure 4B ). To determine that the effect of Ang II specifically increases ET-1 expression in the endothelial cells, cultured endothelial cells were isolated from apoE −/− and Tg(Prkcb)apoE −/− mice and were studied. ET-1 mRNA levels were increased after Ang II stimulation by 2.1-fold in Tg(Prkcb)apoE −/− versus apoE −/− mice (P<0.05; Figure 4C ). Analysis of media incubated with endothelial cells showed that the levels of ET-1 also were significantly higher by 3.6-fold in endothelial cells from Tg(Prkcb)apoE −/− versus apoE −/− mice ( Figure  4D ). Insulin did not increase ET-1 in endothelial cells from either group of mice (data not shown). Because we have reported that PKC-β upregulated ET-1 expression by activation of ERK, 25 basal ERK phosphorylation was studied and was observed to be increased by 1.82±0.90-fold in cells from Tg(Prkcb)apoE −/− mice compared with those from apoE −/− mice ( Figure 4E and 4F ).
Evaluation of Atherosclerotic Lesions in the Aorta
In Tg(Prkcb)apoE −/− mice, the mean area covered by aortic atherosclerotic lesions, as evaluated by en face Sudan IV staining and expressed relative to the whole aortic area, was 1.7-fold higher than that in apoE −/− mice (P<0.05; Figure 5A and 5B). Atherosclerotic plaques increased by 2.16±01.78fold in abdominal aorta from Tg(Prkcb)apoE −/− mice (P<0.05) but were not different in aortic root and aortic arch ( Figure  5C-5E ). Analysis of cross-sections of aortic plaque showed that the SMC content in the plaque of Tg(Prkcb)apoE −/− mice was more than 2-times greater than that in apoE −/− mice (10±4.8% vs 4.2±2.4%; P<0.05; Figure 6A and 6B). Absolute macrophage content, measured by macrophage galactosespecific lectin-2 staining, was increased in Tg(Prkcb)apoE −/− mice compared with apoE −/− mice (162 657.3±71 689.49 vs 68 876.76±34 641.95; P<0.05; Figure 6C and 6D). The content of collagen as measured by aniline blue staining was increased by 2-fold in Tg(Prkcb)apoE −/− mice compared with apoE −/− mice (8203.5±3160.9 vs 3899.7±2794.5; P<0.05; Figure 6E and 6F). Area of necrosis in the plaque was denoted by a lack of staining by trichrome, which indicated the absence of cells and collagen. The necrosis area was 1.99±0.55-times higher in Tg(Prkcb)apoE −/− mice compared with apoE −/− mice (11.0±3.1% vs 5.5±2.5%; P<0.05; Figure 6G and 6H) .
Discussion
In the present study, we have directly demonstrated that overexpression of PKC-β2 in endothelial cells inhibits insulin signaling and insulin action and increases expression of ET-1, resulting in endothelial dysfunction and accelerated atherosclerosis. These findings may help explain the elevated risk for atherosclerosis in diabetic and insulin-resistant states because PKC activation, especially the β-isoform, has been shown to be induced by hyperglycemia or elevated free fatty acids in many vascular tissues. 26 The inhibiting role of PKC-β on insulin activation of eNOS clearly has been shown in endothelial cells from diabetic patients. 15 At the cell signaling level, the vasotropic effects of insulin, such as the activation of eNOS, induction of heme oxygenase-1 and vascular endothelial growth factor, and downregulation of VCAM-1, are mediated through activation of the IRS/PI3K/ Akt pathway. 6, 27, 28 PKC activation, especially β-isoform, has been shown to selectively inhibit this pathway by serine phosphorylation of the p85 subunit of PI3K activation in the endothelial cells. Previous studies of the effects of PKC-β activation and atherosclerosis have used whole-body PKC-β knockout mice or systemic use of PKC-β selective inhibitor, which showed a reduction of atherosclerosis in apoE −/− mice. 17 However, the systemic inhibition of PKC-β isoform cannot attribute its effects to the endothelium specifically because activation of PKC-β isoform by diabetes mellitus and its inhibition have been reported to affect many tissues and functions to regulate multiple metabolic pathways . 29 The present study used mice, with overexpression of PKC-β2 targeted specifically to the endothelial cells by use of the vascular endothelial cell cadherin promoter. The Tg(Prkcb)apoE −/− mice have allowed us to test the idea that PKC-β activation specifically in the endothelial cells can cause vascular-selective insulin resistance, endothelial dysfunction, and accelerated atherosclerosis in the absence of systemic insulin resistance and its metabolic changes. Specific enhancement of PKC-β in the endothelium clearly decreased insulin signaling only in the vascular endothelium without affecting systemic insulin action, indicating that decreasing insulin action on the endothelium will not contribute to systemic insulin resistance, which has been suggested. We have previously identified threonine 86 of the p85 regulatory subunit of PI3K as a possible target of PKC-β activation in endothelial cells. This phosphorylation of p85 decreased the association of IRS1 with p85/PI3K after insulin stimulation. 16 A common characteristic of endothelial dysfunction of diabetes mellitus is the impairment of NO bioavailability because of either decreased production or increased degradation by oxidants. Our new findings clearly showed that the increase in PKC-β expression in endothelial cells inhibited insulin activation of p-Akt/p-eNOS, resulting in decreased NO production. This is supported by the biological effect of the relaxation assay in which aorta from Tg(Prkcb)apoE −/− mice exhibited less response to Ach. Another interesting finding is the arterial response to SNP, which exhibited a hyperactive response in Tg(Prkcb)apoE −/− mice. It is possible that this alteration is a compensatory response to lower ambient levels of NO in Tg(Prkcb)apoE −/− mice. One direct effect of impaired insulinstimulated activation of the PI3K/Akt pathway is the increased expression of VCAM-1, which is normally downregulated by insulin via the IRS/Akt/PI3K pathway. Previously, we have reported that VCAM-1 expression in endothelial cells or in aorta from mice with insulin receptors specifically deleted from the endothelial cells (endothelial insulin receptor and ApoE knockout mice) had upregulation of VCAM-1 and accelerated atherosclerosis. 6 The increase in VCAM-1 expression in Tg(Prkcb)apoE −/− mice also had biological significance because it is associated with elevated binding of leukocytes. The increase in leukocyte binding to the endothelium also was observed in endothelial insulin receptor and ApoE knockout mice. 6 The pathology of the atherosclerotic plaque in Tg(Prkcb)apoE −/− mice was different from endothelial insulin receptor and ApoE knockout mice regarding the increased numbers of SMC compared with apoE −/− mice. The increase in SMC numbers in atherosclerotic plaques could be a result of elevations in proliferation and migration because this is observed in patients with diabetes mellitus and insulin resistance. 30 In fact, some studies have suggested that hyperinsulinemia could be responsible for excessive SMC proliferation, 31 although our recent studies did not support this idea. 32 We also explored the possibility that PKC-β activation directly increased ET-1 expression in the endothelial cells and this effect was exacerbated by Ang II, whose actions are increased in diabetes mellitus. 22 The results from Tg(Prkcb)apoE −/− mice suggest that PKC-β activation in the endothelial cells increased ET-1 expression in the aorta and other arteries from Tg(Prkcb)apoE −/− mice. Increase in the PKC activity has been reported to increase ET-1 expression in several cell types possibly via the MAPK pathway. 23, 25 The additive effect of Ang II in vivo is demonstrated by mRNA levels in the aorta of both genes. Big ET-1 was measured instead of ET-1, because the half-life of ET-1 protein is very short once secreted and protein levels of big ET-1 also were increased. 33 These findings are especially important for understanding the pathogenesis of accelerated atherosclerosis in diabetes mellitus and insulin-resistant states because the activation of PKC-β induced both endothelial dysfunction and SMC activation. The activation of PKC observed in diabetes mellitus or metabolic syndrome could be because of multiple mechanisms, including increased synthesis of diacylglycerol caused by the metabolism of hyperglycemia and elevated free fatty acids. These results clearly demonstrated that PKC-β isoform activation in the endothelium can directly inhibit insulin signaling via the IRS/ PI3K/Akt pathway to decrease eNOS action and reduce NO production, leading to elevation of VCAM-1 and increased monocyte attachment. Our results suggest that the increases in SMC proliferation or migration could be because of elevated expression and action of ET-1 originating from endothelial cells. This could be a direct effect of PKC activation or enhancement of Ang II actions on ET-1 expression in endothelial cells. ET-1 can induce MAPK to induce migration or proliferation, both of which can increase SMC numbers in atherosclerotic plaques.
The increases in atherosclerosis were observed mainly in the descending aorta and not in the root or arch in Tg(Prkcb)apoE −/− mice versus apoE −/− mice. This is comparable with autopsy studies in diabetic patients, which have identified that the extent of atherosclerosis is most significantly increased in the abdominal aorta compared with nondiabetic patients. 34 In addition, the amount of atherosclerosis in the aortic root is not so common in the clinical setting, whereas the extent of atherosclerosis in the abdominal aorta correlates well clinically with atherosclerosis in the coronary artery. In the rodent model, atherosclerosis appears earlier in the aortic root and arch and is more severe than in other parts of the aorta. This has been attributed to differences in heart rate (550 bpm in mice compared with 70 bpm in the average human) and flow. 35 The increase in atherosclerosis in the abdominal aorta in humans is thought to be the result of the turbulent flow. The induction of diabetes mellitus or overexpression of PKC in the endothelium may change the flow from laminar to turbulent in the abdominal aorta and increase atherosclerosis.
The collagen content increased in the plaque of Tg(Prkcb)apoE −/− mice, but they were mainly located around the necrotic core and not on the cap of the lesion. Thus, the findings show an increase in the necrotic cores and the location of the extracellular matrix at the lower part of the plaque near the adventitia, which suggest that the plaques of Tg(Prkcb)apoE −/− mice were not more stable than those of apoE mice.
The overexpression of PKC-β in the endothelium may not be the same as activation of endogenous PKC-β in effecting the function in the endothelium and atherosclerosis. Previously, we have shown that angiotensin activation can cause inhibition of IRS/Akt/eNOS activation in bovine aortic endothelial cells and can enhance MAPK activation. 16 In addition, it targeted threonine 86 phosphorylation of p85/PI3 kinase as shown in Tg(Prkcb)apoE −/− mice ( Figure 1H and  1I) . Thus, we speculate that even without overexpression of PKC-β, the activation of endogenous PKC-β will also inhibit insulin activation of phospho-Akt and eNOS and the loss of inhibition of VCAM-1.
The change of phospho-eNOS in femoral artery after insulin stimulation was not significantly different between the 2 groups of mice; however, the maximum response to insulin was lower in Tg(Prkcb)apoE −/− mice compared with apoE −/− mice. We believe this difference is important because the data shown in Figure 3 regardin the expression of VCAM-1 indicated that the ability of insulin to inhibit VCAM-1 expression is significantly decreased and the basal level of VCAM-1 expression is increased in Tg(Prkcb)apoE −/− mice. Because the inhibitory effect of insulin on VCAM-1 expression is caused by PI3K/Akt pathway, 6 this increased expression of VCAM-1 suggests that the maximum effect attained by insulin through the Akt pathway will have functional significance.
Overexpression of PKC-β seems to decrease apoptosis of the endothelial cells. This is not surprising because PKC-β activation is known to enhance MAPK (Online Figure ID) to decrease apoptosis and increase proliferation in many types of cells. 13 The increase in atherosclerosis exhibited by Tg(Prkcb)apoE −/− mice is likely because of multiple factors, including the inhibition of insulin signaling to activate p-eNOS and lack of inhibition of VCAM-1 expression as shown in Figures 1C, 1D , 3C, and 3F. In addition, it is also likely that PKC-β activation can increase other atherogenic effects, independent of its inhibition of the activation of insulin of the IRS/Akt/eNOS pathway. This is exhibited by the enhanced basal MAPK phosphorylation, which is known to effect PKC activation. In addition, the effect of Ang II to increase ET-1 expression is also elevated independently of insulin. Multiple studies have shown that angiotensin activation can lead to PKC activation and result in actions, including increased expression of ET-1. Because ET-1 expression has been shown to accelerate or exacerbate atherosclerosis, this is likely an insulin signaling-independent pathway by which PKC-β activation enhanced atherosclerosis.
In summary, this study provided definitive evidence that PKC-β activation in the endothelium will accelerate atherosclerosis. In particular, an increase in migration or proliferation of SMC across the internal elastic membrane results in increased production of extracellular matrix. There could be multiple mediators of PKC-β activation that accelerate atherosclerosis, including selective loss of insulin action on p-Akt/eNOS, increase in VCAM-1 expression, elevation of ET-1 expression, and enhancing Ang II effects. These results improve our understanding of the molecular mechanisms of atherogenesis and point to inhibition of PKC-β as a potential strategy for preventing atherosclerosis in insulin resistance, type 2 diabetes mellitus, and other insulin resistance-related diseases.
